PCRX

Pacira BioSciences, Inc.
CAPPED RATING

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Pacira BioSciences, Inc. (PCRX) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (A+); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C+
Factor Score 2.8 / 5.0
Growth
B-
Factor Score 2.9 / 5.0
Profitability
B+
Factor Score 3.8 / 5.0
Momentum
A+
Factor Score 4.5 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 39.2
EV / EBITDA 12.7
Rev Growth YoY -1.6%
Gross Margin 77.9%
Price Return 3M 56.9%
Price Return 12M 52.8%
Catalyst Signal 0.00
Market Cap $1.5B
TTM Revenue $743.3M
Price / Sales 2.0
ROE 5.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.8) B- (2.9) B+ (3.8) A+ (4.5) F (0.0) C+ (2.8)
2026-11-07 B- (2.9) B- (2.9) B+ (3.7) A+ (4.6) F (0.0) C+ (2.8)
2026-10-31 C (2.2) C (2.2) B+ (3.8) B (3.4) F (0.0) C (2.3)
2026-10-24 C (2.2) C (2.2) B+ (3.8) B (3.3) F (0.0) C (2.3)
2026-10-17 C (2.3) C (2.2) B+ (3.8) B (3.2) F (0.0) C (2.3)
Page 1 of 8
…